MoneyWeek’s comprehensive guide to this week’s share tips

Five to buy GSK The Telegraph Although GSK’s shares have declined 9% since last June, the pharmaceuticals giant has delivered a “worthwhile” income. GSK’s dividend is “highly affordable” and growing at a faster pace than inflation, while its yield is higher than the FTSE 100’s. The “cheap” share price compensates for geopolitical risks, and there is scope for a rerating as it bolsters its new drug pipeline. GSK’s capital growth and income-investing appeal offer significant long-term potential. 1...